Updates in Asthma Management by Grant, Jed
University of the Pacific
Scholarly Commons
Physician Assistant Program Faculty Presentations Arthur A. Dugoni School of Dentistry
10-8-2014
Updates in Asthma Management
Jed Grant
University of the Pacific, jgrant@pacific.edu
Follow this and additional works at: https://scholarlycommons.pacific.edu/pa-facpres
Part of the Medicine and Health Sciences Commons
This Conference Presentation is brought to you for free and open access by the Arthur A. Dugoni School of Dentistry at Scholarly Commons. It has
been accepted for inclusion in Physician Assistant Program Faculty Presentations by an authorized administrator of Scholarly Commons. For more
information, please contact mgibney@pacific.edu.
Recommended Citation
Grant, Jed, "Updates in Asthma Management" (2014). Physician Assistant Program Faculty Presentations. 10.
https://scholarlycommons.pacific.edu/pa-facpres/10
1Asthma in Primary Care
Jed Grant, PA-C
Program Director, SJVC PA Program
Staff PA, AMCH Emergency Department
Objectives
 Apply the NAEPP guideline measures of severity and
control including current impairment and future risk to
determine initial and appropriate therapy.
 Identify the six steps of managing asthma for each of
the 3 pediatric age groups of the NAEPP guidelines.
 Know how to assess asthma control through measurable
lung function.
 Identify potential adverse side-effects and indicators of
inadequate treatment of ICS and alternative medication
options to personalize asthma treatment at the time of
initiating long-term control therapy
Epidemiology
 7-10% of population
 500,000 admissions, 4500 deaths
 More common in male children and
female adults
 Genetic predisposition
 Increased incidence of hospitalization in
blacks and children or young adults
– Death rates highest in blacks age 15-24
 Increasing prevalence over last 20 years
CMD&T 2014
Definition
 A disease of diffuse airway
inflammation caused by a variety of
triggering stimuli resulting in partially
or completely reversible
bronchoconstriction.
Merck Manual, 19th ed
Pathophysiology
 Inflammatory cellular infiltrates
– PMN, Eosinophils, Lymphocytes (esp T)
 Goblet cell hyperplasia
– Sometimes with plugging of airways with thick mucus
 Collagen deposition beneath basement
membrane
 Smooth muscle hypertrophy
 Airway edema
 Mast cell activation
 Denuding of airway epithelium
2Predisposing factors
 Atopy
 Obesity
 Allergens/Airway irritants
– Dust mites
– Cockroaches
– Cat dander
– Seasonal pollens
Triggers and Types
 URI
 Aspiration
 GERD
 Weather/Seasonal
changes
 Stress
 Tobacco smoke
 Ozone, particulates
 ASA in some patients
 Environmental
 Occupational
– May have delayed
onset
 Catamenial
(menstrual)
 Exercise induced
 Cardiac
Exercise Induced
Bronchoconstriction
 Begins during exercise or within 3
minutes of terminating exertion
 Peak sx within 10-15 min of onset
 Resolves within 60 min
 Related to airway attempt to humidify
air during exercise
Cardiac Asthma
 Wheezing precipitated by
decompensated CHF
 Result of pulmonary edema rather
than reactive airways
Symptoms
 Episodic
 Dyspnea
 Wheezing
– With normal respiration
– May be absent in severe obstruction
 Breathlessness
 Chest tightness
 Cough
 Prolonged expiratory phase
 Use of accessory muscles
Symptoms
 Highly variable
 May be spontaneous or triggered
 Generally worse at night
– Circadian variation in bronchomotor tone
 NOT wheezing on forced expiration
– “Zombie breathing”
3Diagnosis
 Obstruction easy to find but difficult to
quantify
 Pre/Post Spirometry
– Reduced FEV1/FVC ratio Pre
– Post bronchodilator
 Increase in FEV1 of 12% and 200ml
 Increase in FVC 15% and 200ml
FEV1: Forced Expiratory Volume in 1 second. FVC: Forced Vital Capacity
Diagnosis
 Bronchial provocation testing
(Methylcholine) when spirometry non-
diagnostic
– Not when FEV1 <65% of predicted
– >20% fall in FEV1 positive
– Neg predictive value 95%
 Exercise challenge testing may be helpful
 CXR is NOT helpful unless complication
suspected.
Peak Expiratory Flow (PEF)
 Patient baseline and trend more helpful than
absolute numbers
– PEF varies with height, weight, and gender.
Poorly standardized
 Diurnal variation
– Lowest on awakening, highest midpoint of
awake hours
 >20% change day to day or morning to
afternoon suggests poorly controlled asthma
 <200L/min is poorly controlled asthma
Diagnosis and workup
 PEF is the most useful clinical tool to determine
severity.
 Venous blood gases are useful in the acute phase
– hypercapnia and acidosis occur at PEF <25%
 ABGs are really only appropriate in the clinical
setting of respiratory failure
– Initially normal or respiratory alkalosis
– During more severe exacerbation pCO2 returns to
normal and hypoxemia develops
– Increased pCO2 and respiratory acidosis indicates
impending failure and need for mechanical
ventilation
CXR
 Generally not helpful
– Hyperinflation is usual finding
 May be indicated to rule out
pneumonia in exacerbation
 Useful to diagnose cardiac asthma
(CHF)
Differential Diagnosis
 All that wheezes is not Asthma!
 Upper airway disorders
– FB, vocal cord lesions, tracheomalacia
 Lower airway disorders
– COPD, Bronchiectasis, bronchitis, RSV
 Systemic vasculitidies
 Psychiatric causes (functional asthma)
4Complications
 Exhaustion
 Dehydration
 Infection
 Tussive syncope
 Pneumothorax (rare)
 Respiratory failure
 Death
Treatment Guidelines
 National Asthma Education and
Prevention Program (NAEPP)
– Global Initiative for Asthma (GINA)
– National Institute of Health (NIH)
– National Heart Lung and Blood Institute
(NHLBI)
– World Health Organization (WHO)
– Third expert panel (EP3) in 2007
NAEPP-EP3 Guidelines
 Four main components of Asthma
diagnosis and management
– Assess and monitor severity and control
– Patient education designed to foster a
partnership for care
– Control of environmental factors and
comorbid conditions that effect asthma
– Pharmacologic agents
Assessing and monitoring
severity and control
 Severity is intrinsic intensity of the disease
process
 Control is the degree to which symptoms and
limitations on activity are minimized by
therapy.
– Expressed in terms of impairment and risk
 Impairment: frequency and intensity of sx
 Risk: likelyhood of acute exacerbation or chronic
decline in lung function
 Responsiveness is the ease with which control
is achieved.
Severity of Asthma
 Determined by severity and or
frequency of symptoms
– Night-time awakenings
– Use of SABA
– PEF or FEV1
 Intermittent or persistent
 Logs are very helpful
SABA: Short Acting Beta Agonist
Initiating Treatment
 Asses the severity and impairment of the
patient based on historical symptoms
and/or PEF.
 Go to the area on the chart that
corresponds to the patients symptoms
and start at that level.
 Helpful to know normal FEV1/FVC
– Around 80% for most adults, normal decline
with age.
5Severity of Asthma Initiating Treatment
ICS: Inhaled corticosteroid. LABA: Long Acting Beta Agonist.
Assessing Control Asthma
Control
Test
 There are
different types
of tests to
help the
patient
quantify
symptoms.
 Objective
measure of
control.
Age 0-4 Age 5-11
LTRA: Leukotriene Receptor Antagonist.
6Age >12 Acute Treatment
 Short acting Beta-adrenergic agonists
– Albuterol
– Levalbuterol
– Bitolterol
– Pirbuterol
– Terbutaline
– 6-12 puffs/hr = one HHN
 Anticholinergics
– Ipratropium bromide
– One HHN/0.5mg in acute exacerbation
 No response; send to ER
Emergency Treatment
 Check theophylline level if they are
taking it, but no other role in acute
exacerbation
 Corticosteroids
– Methylprednisolone
– Prednisone
 Consider CXR, ABX if fever or purulent
sputum
Emergency Treatment
 Oxygen to maintain SaO2 of >90%
 MgSO4: 2g IV over 20 min
 Mechanical ventilation/admission
– Ketamine for induction
 Heliox?
– Not used if hypoxic
 Inhaled general anesthetic?
 NO mucolytics, anxiolytics, hypnotics
Control of mild/moderate
exacerbations
 USE CHARTS
 Mild exacerbation
– Beta agonist at increased doses
– Add inhaled corticosteroid, or short
course of PO steroid if already on inhaled
steroids
 Doubling dose of ICS is not effective and is
no longer recommended
Control of mild/moderate
exacerbations
 Moderate exacerbation
– 3 HHN of beta agonist in 1 hour
– Systemic corticosteroids
 PO or IV
– Observe
– IF better after 3 HHN home on PO
steroids
– If not better send to ER
7Long Term Treatment
 Anti-inflammatory agents
– ICS (preferred first line agents)
– May have additive effect with B agonists
– Maximal effect takes months
– Use of spacer and mouth wash after dose
very important to limit side effects and
systemic absorption
– Systemic corticosteroids
 Taper not needed under 10 days
Pharmacodymics of ICS
Inhaled Corticosteroids
Drug Low Dose (24hrs) High Dose (24 hrs)
Beclomethasone HFA
40 or 80 mcg
80-240mcg >480mcg
Budesonide DPI
90, 180, or 200 mcg
180-600mcg >1200mcg
Flunisolide
250mcg
500-1000mcg >2000mcg
Flunisolide HFA
80mcg
320mcg >640mcg
Fluticasone
HFA 44,110,220 mcg
DPI 50,100,250mcg
88-264mcg
100-300mcg
>440mcg
>500mcg
Mometasone DPI
200mcg
200mcg >400mcg
Triamcinolone acetonide
75mcg
300-750 mcg >1500mcg
Long term treatment
 Long acting bronchodilators
– Mast cell stabilizers
 Cromolyn, nedocromil
 Response less predictable than ICS/CS
 May take 4-6 weeks to see maximal response
– Long acting Beta adrenergic agonists (LABA)
 Salmeterol, formoterol
 Dry powder delivery
 Available combined with steroids in one MDI
 NOT for acute or mono-therapy use
– Phosphodiesterase inhibitors
 Theophylline
– Narrow therapeutic window
Long Term Treatment
 Anticholinergic
– Tiotropium
 Long acting
 Add on therapy when low dose ICS is not adequate
 Leukotriene modifiers
– Leukotrienes are biochemical mediators which
increase inflammation, vascular permeability, mucus
secretion and smooth muscle contraction
– Alternative to low dose ICS or add on equivalent to
LABA
– Montelukast, zafirlukast are LTRAs.
– Zileuton has different MOA and can cause elevated
ALT levels
Long Term Treatment
 Desensitization
– Best for known trigger
 Immunotherapy
– Omalizumab- recominant Ab that binds
IgE without activating mast cells
 Vaccination
– Pneumovax and flu
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